Holen Sie sich die Stockscreener-App
3.20
1.54%
-0.05
Schlusskurs vom Vortag:
$3.25
Offen:
$3.3
24-Stunden-Volumen:
3.70M
Relative Volume:
2.31
Marktkapitalisierung:
$543.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-236.30M
KGV:
-2.1868
EPS:
-1.4633
Netto-Cashflow:
$-208.07M
1W Leistung:
+50.94%
1M Leistung:
+49.53%
6M Leistung:
+105.13%
1J Leistung:
+89.35%
1-Tages-Spanne:
$3.14
$3.35
1-Wochen-Bereich:
$2.085
$3.465
52-Wochen-Spanne:
$0.611
$3.465
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
3.20 | 552.30M | 0 | -236.30M | -208.07M | -1.4633 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics (NASDAQ:NMRA) Sets New 1-Year HighHere's What Happened - MarketBeat
NMRA: NMRA-511 shows strong efficacy in Alzheimer's agitation; pipeline and cash runway support growth - TradingView
Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora - TipRanks
Neumora Therapeutics, Inc. Presents NMRA-511 Efficacy at Biotech Summit - TradingView
Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st
Neumora Therapeutics (NASDAQ:NMRA) Trading Up 25.3%What's Next? - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Resistance Check: Should I buy Neumora Therapeutics Inc stock nowPortfolio Update Report & Expert Verified Movement Alerts - baoquankhu1.vn
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Short Interest in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Drops By 20.2% - MarketBeat
ETF Watch: Will Neumora Therapeutics Inc stock go up in YEAR2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Will Neumora Therapeutics Inc. stock go up in YEAR2025 Year in Review & Growth Focused Entry Reports - mfd.ru
FY2030 Earnings Estimate for NMRA Issued By HC Wainwright - MarketBeat
Stop Loss: Can QMMM Holdings Limited navigate macro headwindsQuarterly Market Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Investment Review: What makes SZZLU stock attractive todayInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Targets Report: Can AZEK continue delivering strong returnsQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Volume Report: Is Neumora Therapeutics Inc showing insider buying2025 Fundamental Recap & Weekly Return Optimization Alerts - baoquankhu1.vn
Earnings Beat: Should I hold or sell SPCE nowMarket Weekly Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
RSI Check: Is Neumora Therapeutics Inc benefiting from innovation trends2025 Short Interest & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Wrap: Is Castle Biosciences Inc vulnerable to short sellersVolume Spike & Breakout Confirmation Alerts - baoquankhu1.vn
Why Neumora Therapeutics Inc stock appeals to analystsProduct Launch & Smart Allocation Stock Reports - Bộ Nội Vụ
Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Leerink Partnrs - MarketBeat
Leerink Partners Initiates Coverage of Neumora Therapeutics (NMRA) with Outperform Recommendation - Nasdaq
Leerink Partners Begins Coverage on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Leerink Initiates Neumora Therapeutics at Outperform With $8 Price Target - marketscreener.com
Neumora outlines 2026 neuroscience pipeline and obesity plans - TipRanks
Neumora Therapeutics, Inc. Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating - TipRanks
Leerink Partners initiates coverage on Neumora stock with Outperform rating By Investing.com - Investing.com Canada
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Is Neumora Therapeutics Inc. stock a defensive play in 2025Gap Down & Advanced Technical Analysis Signals - Улправда
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances - RTTNews
Published on: 2026-01-12 18:50:31 - ulpravda.ru
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses - MarketBeat
Trend Review: What hedge fund activity signals for Neumora Therapeutics Inc. stockJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - Улправда
Can Neumora Therapeutics Inc. stock beat market expectations this quarterVolume Analysis Techniques & Turn Data into Profits With Our Strategies - Улправда
How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine - Investor's Business Daily
Mizuho reiterates Outperform rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY) - The Globe and Mail
Neumora outlines 2026 pipeline milestones for neuroscience programs By Investing.com - Investing.com Nigeria
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target - TipRanks
Mizuho raises Neumora Therapeutics stock price target on positive trial data - Investing.com Canada
Neumora shares climb after encouraging Phase 1b results for Alzheimer’s agitation therapy - MSN
Why Is Neumora Therapeutics Stock Gaining Monday?Neumora Therapeutics (NASDAQ:NMRA) - Benzinga
Neumora's Alzheimer's Agitation Drug Shows Early Promise - Sahm
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug - Investing.com Nigeria
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug By Investing.com - Investing.com South Africa
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):